Bacinschi Xenia Elena, Zgura Anca, Safta Inga, Anghel Rodica
Department of Oncology-Radiotherapy, Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania.
University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Cancer Manag Res. 2020 Nov 20;12:11965-11971. doi: 10.2147/CMAR.S274104. eCollection 2020.
Treatment of triple-negative breast cancer is challenging. Standard adjuvant tretment is considered to be the cobination of anthracycline and taxanes although the role of anthracyclines administered preoperatively remains controversial. Actually, some studies recommended taxane-only regimens. We reviewed literatures to examine whether tissue biomarkers available in an ordinary laboratory setting (eg, haematoxylin and eosin and immunohistochemistry) may predict response to adjuvant anthracyclines in patients with triple-negative breast cancer. Our review showed that Bcl-2, p53, and tumor-infiltrating lymphocytes (TILs) expression may become independent predictors for triple-negative breast cancer. This finding was based on data from retrospective studies, and, thus, randomized controlled study is needed to confirm the present results.
三阴性乳腺癌的治疗具有挑战性。标准辅助治疗被认为是蒽环类药物和紫杉烷类药物的联合使用，尽管术前使用蒽环类药物的作用仍存在争议。实际上，一些研究推荐仅使用紫杉烷类药物的治疗方案。我们回顾了文献，以研究普通实验室环境下可用的组织生物标志物（如苏木精和伊红染色及免疫组织化学）是否可预测三阴性乳腺癌患者对辅助性蒽环类药物的反应。我们的综述表明，Bcl-2、p53和肿瘤浸润淋巴细胞（TILs）的表达可能成为三阴性乳腺癌的独立预测指标。这一发现基于回顾性研究的数据，因此，需要进行随机对照研究来证实目前的结果。
